Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO GI 2022 Highlights
Novel Vaccine plus Chemotherapy Shows Promise in the Treatment of Metastatic Pancreatic Cancer
By
Wayne Kuznar
ASCO GI 2022 Highlights
April 2022, Vol 13, No 2
Interim results from a phase 2 clinical trial showed that a novel combination of aldoxorubicin, N-803 (an IL-15 superagonist), and PD-L1 natural killer cell therapy (Nant Cancer Vaccine) plus low-dose chemotherapy doubled overall survival (OS) compared with historical controls in patients with locally advanced or metastatic pancreatic cancer.
Read Article
Pembrolizumab Added to Best Supportive Care Extends Survival in Advanced HCC
By
Wayne Kuznar
ASCO GI 2022 Highlights
April 2022, Vol 13, No 2
Pembrolizumab (Opdivo) added to best supportive care (BSC) improved outcomes including overall survival (OS) versus BSC alone in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib (Nexavar), according to final results from the KEYNOTE-394 trial.
Read Article
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers
By
Phoebe Starr
ASCO GI 2022 Highlights
April 2022, Vol 13, No 2
Trastuzumab deruxtecan (Enhertu; T-DXd) continues to show superior antitumor activity and improved survival compared with standard chemotherapy in patients with advanced
HER2
-expressing gastric or gastroesophageal junction (GEJ) cancer, according to updated results from the phase 2 DESTINY-Gastric01 trial. T-DXd is an antibody–drug conjugate comprising an anti-
HER2
antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor.
Read Article
AK104 plus Chemotherapy Shows Promise in Patients with Advanced Gastric Cancers
By
Wayne Kuznar
ASCO GI 2022 Highlights
April 2022, Vol 13, No 2
The PD-1/CTLA-4 bispecific antibody, AK104, plus chemotherapy represents a potential new first-line treatment option for patients with advanced gastric or gastroesophageal junction (GEJ) cancer.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma